StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) stock

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.45+0.30 (+13.95%)

Close on Nov 17, 2026Market cap $106.08MP/E –Yield –

NRX Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

NRX Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.41M, up 57.4% year over year. For fiscal 2025 it was $3.78M, down 39.1% from the year before. The highest annual figure on record is $20.26M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.78M-39.1%
FY2024Dec 31, 2024$6.20M-53.6%
FY2023Dec 31, 2023$13.37M-21.5%
FY2022Dec 31, 2022$17.03M-15.9%
FY2021Dec 31, 2021$20.26M+90.7%
FY2020Dec 31, 2020$10.63M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.12M+114.4%
Q1 FY2026Mar 31, 2026$1.31M+62.8%
Q4 FY2025Dec 31, 2025$558.00K-46.1%
Q3 FY2025Sep 30, 2025$1.43M+133.9%
Q2 FY2025Jun 30, 2025$987.00K-64.8%
Q1 FY2025Mar 31, 2025$804.00K-54.0%
Q4 FY2024Dec 31, 2024$1.04M-59.1%
Q3 FY2024Sep 30, 2024$611.00K-81.6%
Q2 FY2024Jun 30, 2024$2.80M-27.6%
Q1 FY2024Mar 31, 2024$1.75M+117.4%
Q4 FY2023Dec 31, 2023$2.53M-43.1%
Q3 FY2023Sep 30, 2023$3.31M-19.7%
Q2 FY2023Jun 30, 2023$3.87M+30.9%
Q1 FY2023Mar 31, 2023$804.00K-85.3%
Q4 FY2022Dec 31, 2022$4.46M-30.5%
Q3 FY2022Sep 30, 2022$4.13M-34.2%
Q2 FY2022Jun 30, 2022$2.96M-36.5%
Q1 FY2022Mar 31, 2022$5.48M+88.5%
Q4 FY2021Dec 31, 2021$6.41M+49.2%
Q3 FY2021Sep 30, 2021$6.28M+44.9%
Q2 FY2021Jun 30, 2021$4.66M+235.1%
Q1 FY2021Mar 31, 2021$2.91M–
Q4 FY2020Dec 31, 2020$4.30M–
Q3 FY2020Sep 30, 2020$4.33M–
Q2 FY2020Jun 30, 2020$1.39M–

More NRX Pharmaceuticals figures

See a number that looks wrong?